Clinical trials on drug repositioning for COVID-19 treatment.
Identifieur interne : 000320 ( PubMed/Curation ); précédent : 000319; suivant : 000321Clinical trials on drug repositioning for COVID-19 treatment.
Auteurs : Sandro G Viveiros Rosa [Brésil] ; Wilson C. Santos [Brésil]Source :
- Revista panamericana de salud publica = Pan American journal of public health [ 1680-5348 ] ; 2020.
Abstract
The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.
DOI: 10.26633/RPSP.2020.40
PubMed: 32256547
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000320
Links to Exploration step
pubmed:32256547Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical trials on drug repositioning for COVID-19 treatment.</title><author><name sortKey="Rosa, Sandro G Viveiros" sort="Rosa, Sandro G Viveiros" uniqKey="Rosa S" first="Sandro G Viveiros" last="Rosa">Sandro G Viveiros Rosa</name><affiliation wicri:level="1"><nlm:affiliation>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro</wicri:regionArea></affiliation></author><author><name sortKey="Santos, Wilson C" sort="Santos, Wilson C" uniqKey="Santos W" first="Wilson C" last="Santos">Wilson C. Santos</name><affiliation wicri:level="1"><nlm:affiliation>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32256547</idno><idno type="pmid">32256547</idno><idno type="doi">10.26633/RPSP.2020.40</idno><idno type="wicri:Area/PubMed/Corpus">000320</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000320</idno><idno type="wicri:Area/PubMed/Curation">000320</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000320</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical trials on drug repositioning for COVID-19 treatment.</title><author><name sortKey="Rosa, Sandro G Viveiros" sort="Rosa, Sandro G Viveiros" uniqKey="Rosa S" first="Sandro G Viveiros" last="Rosa">Sandro G Viveiros Rosa</name><affiliation wicri:level="1"><nlm:affiliation>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro</wicri:regionArea></affiliation></author><author><name sortKey="Santos, Wilson C" sort="Santos, Wilson C" uniqKey="Santos W" first="Wilson C" last="Santos">Wilson C. Santos</name><affiliation wicri:level="1"><nlm:affiliation>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.</nlm:affiliation><country xml:lang="fr">Brésil</country><wicri:regionArea>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro</wicri:regionArea></affiliation></author></analytic><series><title level="j">Revista panamericana de salud publica = Pan American journal of public health</title><idno type="eISSN">1680-5348</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus <i>Betacoronavirus</i>, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32256547</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1680-5348</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>Revista panamericana de salud publica = Pan American journal of public health</Title><ISOAbbreviation>Rev. Panam. Salud Publica</ISOAbbreviation></Journal><ArticleTitle>Clinical trials on drug repositioning for COVID-19 treatment.</ArticleTitle><Pagination><MedlinePgn>e40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.26633/RPSP.2020.40</ELocationID><Abstract><AbstractText>The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus <i>Betacoronavirus</i>, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosa</LastName><ForeName>Sandro G Viveiros</ForeName><Initials>SGV</Initials><AffiliationInfo><Affiliation>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Wilson C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>Universidade Federal Fluminense Universidade Federal Fluminense Brazil Universidade Federal Fluminense, Rio de Janeiro, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Rev Panam Salud Publica</MedlineTA><NlmUniqueID>9705400</NlmUniqueID><ISSNLinking>1020-4989</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText>En diciembre de 2019 fue informado a la Organización Mundial de la Salud (OMS) un brote de neumonía por coronavirus en Wuhan, provincia de Hubei, China. Al 12 de marzo de 2020, se habían notificado 125 048 casos y 4 614 muertes. El coronavirus es un virus ARN envuelto del género <i>Betacoronavirus</i> distribuido en aves, seres humanos y otros mamíferos. La OMS ha denominado a la nueva enfermedad por coronavirus COVID-19. Se han puesto en marcha más de 80 ensayos clínicos para evaluar un tratamiento para el coronavirus, que incluyen algunos ensayos de reposicionamiento de medicamentos para la COVID-19. En marzo de 2020 se llevó a cabo una búsqueda de los ensayos clínicos registrados en la base de datos clinicaltrials.gov. Los criterios de elegibilidad para los estudios recuperados fueron tener un número de identificación de la base de datos clinicaltrials.gov; describir el número de participantes y el período del estudio; describir las condiciones clínicas de los participantes; y emplear intervenciones con medicamentos ya estudiados o aprobados para cualquier otra enfermedad en pacientes infectados con el nuevo coronavirus SARS-CoV-2 (2019-nCoV). Es esencial destacar que este artículo solo recoge los ensayos que figuran en la base de datos clinicaltrials. gov. Se identificaron 24 ensayos clínicos relacionados con más de 20 medicamentos, como inmunoglobulina humana, interferones, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumab y medicina tradicional china. Aunque el reposicionamiento de medicamentos tiene algunas limitaciones, el reposicionamiento de los ensayos clínicos puede representar una estrategia atractiva porque facilita el descubrimiento de nuevas clases de medicamentos; estos tienen costos más bajos y tardan menos en llegar al mercado; y existen cadenas de suministro farmacéutico que apoyan la formulación y la distribución.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="por"><AbstractText>A Organização Mundial da Saúde (OMS) foi informada, em dezembro de 2019, sobre um surto de pneumonia por coronavírus em Wuhan, província de Hubei (China). Posteriormente, em 12 de março de 2020, 125 048 casos e 4 614 mortes haviam sido registrados. O coronavírus é um vírus RNA envelopado do gênero <i>Betacoronavírus,</i> distribuído em aves e em humanos e outros mamíferos. A OMS designou a nova doença por coronavírus como COVID-19. Mais de 80 ensaios clínicos foram iniciados para testar tratamentos para o coronavírus, incluindo alguns de reposicionamento de medicamentos para o COVID-19. Assim, em março de 2020 realizou-se uma busca na base de dados clinicaltrials.gov. Os critérios de elegibilidade para os estudos recuperados foram: conter o número identificador da base de dados clinicaltrials.gov; descrever o número de participantes e o período do estudo; descrever as condições clínicas dos participantes; e utilizar intervenções para tratamento de doentes infectados com o novo coronavírus SARS-CoV-2 (2019-nCoV) com medicamentos já estudados ou aprovados para qualquer outra doença. É essencial salientar que este artigo apenas capturou ensaios listados na base de dados clinicaltrials.gov. Foram identificados 24 ensaios clínicos envolvendo mais de 20 medicamentos, tais como imunoglobulina humana, interferons, cloroquina, hidroxicloroquina, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, metilprednisolona, bevacizumabe e medicamentos chineses tradicionais. Embora o reposicionamento de medicamentos tenha algumas limitações, os ensaios clínicos de reposicionamento podem representar uma estratégia atraente, porque facilitam a descoberta de novas classes de medicamentos, têm custos mais baixos, levam menos tempo para chegar ao mercado e se beneficiam de cadeias de fornecimento farmacêutico já existentes para formulação e distribuição.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug repositioning</Keyword><Keyword MajorTopicYN="N">clinical trials as topic</Keyword><Keyword MajorTopicYN="N">coronavirus infection</Keyword><Keyword MajorTopicYN="N">pandemics</Keyword><Keyword MajorTopicYN="N">pneumonia, viral</Keyword><Keyword MajorTopicYN="N">virus diseases</Keyword></KeywordList><CoiStatement>Conflicts of interest. None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>02</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32256547</ArticleId><ArticleId IdType="doi">10.26633/RPSP.2020.40</ArticleId><ArticleId IdType="pii">RPSP.2020.40</ArticleId><ArticleId IdType="pmc">PMC7105280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Virol. 2004 Dec;31(4):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15494274</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2014 Jul;107:84-94</Citation><ArticleIdList><ArticleId IdType="pubmed">24769245</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Autoimmun Rev. 2016 Jan;15(1):71-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26384525</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Discov Today. 2019 Mar;24(3):726-736</Citation><ArticleIdList><ArticleId IdType="pubmed">30711575</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trials. 2018 Jan 30;19(1):81</Citation><ArticleIdList><ArticleId IdType="pubmed">29382391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMJ. 2019 Aug 13;366:l5140</Citation><ArticleIdList><ArticleId IdType="pubmed">31409588</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2020 Mar 18;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Pharmacol Ther. 2010 Mar;87(3):322-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20043009</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Anticancer Res. 2019 Nov;39(11):5891-5901</Citation><ArticleIdList><ArticleId IdType="pubmed">31704813</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trends Microbiol. 2018 Oct;26(10):865-876</Citation><ArticleIdList><ArticleId IdType="pubmed">29759926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Chin Med. 2019;47(6):1223-1235</Citation><ArticleIdList><ArticleId IdType="pubmed">31505937</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 2019 Jun;35(6):513-518</Citation><ArticleIdList><ArticleId IdType="pubmed">30909716</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Immunol. 2014;32:513-45</Citation><ArticleIdList><ArticleId IdType="pubmed">24555472</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Discov Today. 2019 Jan;24(1):1-3</Citation><ArticleIdList><ArticleId IdType="pubmed">29936247</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2019 Jan;18(1):41-58</Citation><ArticleIdList><ArticleId IdType="pubmed">30310233</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2007 Oct;30(4):297-308</Citation><ArticleIdList><ArticleId IdType="pubmed">17629679</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2018 May 2;66(10):1501-1503</Citation><ArticleIdList><ArticleId IdType="pubmed">29315362</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2020 Mar;19(3):149-150</Citation><ArticleIdList><ArticleId IdType="pubmed">32127666</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Angiogenesis. 2004;7(4):335-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15886877</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drugs. 2018 Aug;78(12):1271-1276</Citation><ArticleIdList><ArticleId IdType="pubmed">30117020</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nutrients. 2020 Jan 22;12(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">31978969</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur Rev Med Pharmacol Sci. 2018 Aug;22(15):4956-4961</Citation><ArticleIdList><ArticleId IdType="pubmed">30070331</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2020 Feb 7;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2020 Feb 5;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32022836</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Oct 25;362(9393):1353-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14585636</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2162-2164</Citation><ArticleIdList><ArticleId IdType="pubmed">32141586</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Anti Infect Ther. 2017 Mar;15(3):269-275</Citation><ArticleIdList><ArticleId IdType="pubmed">27937060</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000320 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000320 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32256547
|texte= Clinical trials on drug repositioning for COVID-19 treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32256547" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |